Gabizon A - Search Results

1

Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA).

Patil Y, Shmeeda H, Amitay Y, Ohana P, Kumar S, Gabizon A. Patil Y, et al. Among authors: gabizon a. Nanomedicine. 2018 Jun;14(4):1407-1416. doi: 10.1016/j.nano.2018.04.011. Epub 2018 Apr 19. Nanomedicine. 2018. PMID: 29680672

2

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.

Gabizon A, Shmeeda H, Barenholz Y. Gabizon A, et al. Clin Pharmacokinet. 2003;42(5):419-36. doi: 10.2165/00003088-200342050-00002. Clin Pharmacokinet. 2003. PMID: 12739982 Review.

3

In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.

Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S. Gabizon A, et al. Clin Cancer Res. 2003 Dec 15;9(17):6551-9. Clin Cancer Res. 2003. PMID: 14695160

4

Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates.

Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Gabizon A, et al. Adv Drug Deliv Rev. 2004 Apr 29;56(8):1177-92. doi: 10.1016/j.addr.2004.01.011. Adv Drug Deliv Rev. 2004. PMID: 15094214 Review.

5

Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors.

Shmeeda H, Mak L, Tzemach D, Astrahan P, Tarshish M, Gabizon A. Shmeeda H, et al. Among authors: gabizon a. Mol Cancer Ther. 2006 Apr;5(4):818-24. doi: 10.1158/1535-7163.MCT-05-0543. Mol Cancer Ther. 2006. PMID: 16648551

6

An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin.

Gabizon A, Isacson R, Rosengarten O, Tzemach D, Shmeeda H, Sapir R. Gabizon A, et al. Cancer Chemother Pharmacol. 2008 Apr;61(4):695-702. doi: 10.1007/s00280-007-0525-5. Epub 2007 Jun 5. Cancer Chemother Pharmacol. 2008. PMID: 17549475 Clinical Trial.

7

Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.

Shmeeda H, Tzemach D, Mak L, Gabizon A. Shmeeda H, et al. Among authors: gabizon a. J Control Release. 2009 Jun 5;136(2):155-60. doi: 10.1016/j.jconrel.2009.02.002. Epub 2009 Feb 7. J Control Release. 2009. PMID: 19331844

8

Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.

Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S. Gabizon A, et al. Cancer Chemother Pharmacol. 2010 May;66(1):43-52. doi: 10.1007/s00280-009-1132-4. Epub 2009 Sep 25. Cancer Chemother Pharmacol. 2010. PMID: 19779718

9

Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells.

Shmeeda H, Amitay Y, Gorin J, Tzemach D, Mak L, Ogorka J, Kumar S, Zhang JA, Gabizon A. Shmeeda H, et al. Among authors: gabizon a. J Control Release. 2010 Aug 17;146(1):76-83. doi: 10.1016/j.jconrel.2010.04.028. Epub 2010 May 10. J Control Release. 2010. PMID: 20462513

10

Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy.

Gabizon A, Shmeeda H, Grenader T. Gabizon A, et al. Eur J Pharm Sci. 2012 Mar 12;45(4):388-98. doi: 10.1016/j.ejps.2011.09.006. Epub 2011 Sep 10. Eur J Pharm Sci. 2012. PMID: 21933707 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

148 results

Search Page

Filters